Under the terms of the agreement, Amesys will develop a portable system that will enable patients to move around independently and safely in their daily activities. The user-friendly equipment will allow the patient to live at home and travel around. This system will be available by early 2012, in time for the hospital-to-home discharge of the first clinical-phase recipients of the CARMAT heart.
"This agreement with Bull will enable the first patients to return home under good conditions", emphasized CARMAT CEO Marcello Conviti. "The patient's quality of life has always been a crucial parameter in CARMAT's development philosophy".
"We are delighted with this collaboration and CARMAT's renewed confidence. Our technical rigour and expertise in mission-critical systems are at CARMAT's full disposal", added Olivier Jolland (Chief Operating Officer at Amesys). "We shall have to find a balance between mobility, autonomy and maximum reliability for the CARMAT system", he added.
CARMAT offers a response to a major public health issue associated with heart disease, the world’s leading cause of death: chronic and acute heart failure. Indeed, this disease currently affects over 20 million patients in developed countries. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from heart failure
The Bull subsidiary Amesys has already provided CARMAT with monitoring equipment that will be used in hospital, during the post-surgery phase and for follow-up visits. These specific solutions call on Amesys' acknowledged skills in the integration and management of mission-critical systems projects that combine high-reliability electronic and mechanical modules.
About Bull
Bull is an IT company dedicated to helping private- and public-sector organizations optimize the architecture, operations and financial return of their business-critical information system. Bull focuses on open and secure systems and is the only European-based company offering expertise in all the key links in the IT value chain For more information: www.bull.fr
PAR-#3442506-v1 2/2
About CARMAT: CARMAT, the world’s most advanced total artificial heart project.
The only credible response for all cases of end-stage heart failure, which is a real public health issue: CARMAT aims is to provide a response to a major public health issue associated with heart disease, the world’s leading cause of death: chronic and acute heart failure. Indeed, this disease currently affects over 20 million patients in developed countries. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from advanced heart failure.
The result of combining two types of unique expertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of EADS, world aerospace leader.
Imitating the natural heart: given its size, its weight, the choice of structural materials and its innovative physiological functions, CARMAT’s total artificial heart could, assuming upcoming clinical trials are successful, potentially benefit the lives of tens of thousands of patients a year whilst ensuring there is no risk of rejection and providing them with an unparalleled quality of life.
A project leader acknowledged at a European level: with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by OSEO; a total of €33 million.
Strongly committed, prestigious founders and shareholders: Truffle Capital (the leading European venture capital firm), EADS, the Foundation Alain Carpentier and the thousands of institutional and individual shareholders who have placed their trust in CARMAT.
For more information: www.carmatsas.com
Disclaimer This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in Carmat ("the Company") in any country. This press release contains forward-looking statements that relate to the Company’s objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company’s management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavourable developments in connection with these and other risks and uncertainties described, in particular, in the Company’s Document de Référence registered with the French Autorité des marches financiers (“AMF”) on 27 April 2011 under number R. 11 - 017 together with the Note d’Opération approved by the AMF under visa number 11-108 on 11 July 2010, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
PRESS CONTACTS
CARMAT
Valérie Leroy
Director, Marketing & Investor Relations
Tel. : +33 (0)1 39 45 64 50
investisseurs@carmatsas.com
Bull
Barbara Coumaros
Press relations
Tel.: +33 (0)6 85 52 84 84
barbara.coumaros@bull.net
Alizé RP
Corporate communications/ press relations
Caroline Carmagnol
Tel.: +33 (0)1 42 68 86 43
caroline@alizerp.com
